Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04671732
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2020-12-11
Brief Title:
Cost-utility Analysis of Fenestrated Aortic Stents Versus Open Surgery for the Treatment of Complex Abdominal Aortic Aneurysms
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Cost-utility Analysis of Fenestrated Aortic Stents Versus Open Surgery for the Treatment of Complex Abdominal Aortic Aneurysms a Prospective Multicenter Comparative Cohort Study
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ORFEVAR
Brief Summary:
Introduction Complex abdominal aortic aneurysms CAA are defined as abdominal aneurysms that are anatomically unsuitable for a standard endovascular repair because of a short infrarenal neck or no infrarenal neck These CAAA are usually treated either by fenestrated endovascular aortic repair FEVAR or open repair OR Data comparing these thechniques remain scarce mainly consisting of systematic reviews based on retrospective studies Although mid-term and long-term results remain uncertain FEVAR has gained widespread acceptance in the vascular community However this practice is not evidence base Beyond clinical results whether FEVAR is cost-effective or not is not demonstrated A randomized controlled trial comparing FEVAR and OR is unlikely to be conducted since centers have developed specific expertise and practice and most of surgeons are not keen to randomize patients Thus we believe that a prospective comparative multicentric cohort with a propensity score and minimization of selection classification and confusion bias is the most realistic way to provide reliable comparative data on cost effectiveness of FEVAR and OR Overall 382 patients are expected to be included 159 in each group
Objective The objective of this prospective non-randomized comparative multicenter cohort study is to compare the cost effectiveness incremental ratio at 36 months of FEVAR and OR for CAAA
Method Patients with CAAA discussed for FEVAR or OR in 37 french vascular centers in during a two years inclusion period constitute the population study Preoperative and postoperative clinical and imaging data will are collected prospectively in eCRF forms QOL before and after treatment is assessed by the E5D5L The follow-up period is three years The primary outcome is the Incremental cost-utility ratio costQALY at 36 months We plan to minimize indication biases by using a proposensity score proposnsity score maching and Inverse probablility of treatment weighting based on clinical and anatomic characteristics Patient at prohibitive risk for OR are excluded Patient anatomically unsuitable for FEVAR are also excluded
Conclusion This study should provided valuable data on cost effectiveness of FEVAR for CAAA Sub-goup analysis will be also conducted
Objective The objective of this prospective non-randomized comparative multicenter cohort study is to compare the cost effectiveness incremental ratio at 36 months of FEVAR and OR for CAAA
Method Patients with CAAA discussed for FEVAR or OR in 37 french vascular centers in during a two years inclusion period constitute the population study Preoperative and postoperative clinical and imaging data will are collected prospectively in eCRF forms QOL before and after treatment is assessed by the E5D5L The follow-up period is three years The primary outcome is the Incremental cost-utility ratio costQALY at 36 months We plan to minimize indication biases by using a proposensity score proposnsity score maching and Inverse probablility of treatment weighting based on clinical and anatomic characteristics Patient at prohibitive risk for OR are excluded Patient anatomically unsuitable for FEVAR are also excluded
Conclusion This study should provided valuable data on cost effectiveness of FEVAR for CAAA Sub-goup analysis will be also conducted
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None